Diagnosis of Lung Cancer – Improving Survival Rates

European Oncology, 2010;6(2):26-30


Lung cancer is a major global health burden with high incidence rates but poor long-term survival. Currently, the majority of cases are diagnosed at an advanced stage when surgical resection is not feasible. Screening for lung cancer has been a major focus of research for the last 40 years. Despite this, there is still a lack of evidence to promote its use outside clinical trials. More recently, interest has focused on promoting earlier recognition of symptomatic disease among both the general public and primary care physicians in order to encourage more timely investigation and referral to secondary care. The hope is that this approach may increase the proportion of disease identified in the early stages, allowing more surgical resections and improved five-year survival rates. This article provides an overview of the current evidence base in terms of early diagnosis of lung cancer and provides some examples of innovations to promote this.
Keywords: Lung cancer, early diagnosis, screening, social marketing
Disclosure: The authors have no conflicts of interest to declare.
Received: July 01, 2010 Accepted July 29, 2010 Citation European Oncology, 2010;6(2):26-30
Correspondence: Victoria L Athey, Clinical Research Fellow, Chest Clinic, Doncaster Royal Infirmary, Armthorpe Road, Doncaster, DN2 5LT, UK. E: v.athey@sheffield.ac.uk

Lung cancer is a major global health burden: it was responsible for 1.3 million deaths in 2004, equating to 2.3% of all deaths. Death rates from lung cancer are predicted to continue to rise, with the disease being responsible for 2.8% of all deaths (1.67 million) by 2015.1

Despite advances in treatment, survival rates from lung cancer in the UK have improved by only a few per cent in the last 40 years. The fiveyear survival rate for patients diagnosed between 1991 and 1993 was 5%.2 The EUROpean CAncer REgistry-based study on survival and CARE of cancer patients 4 (EUROCARE-4)3 has highlighted the difference in survival between England and other European countries. The fiveyear survival rate in England for patients diagnosed between 1995 and 1999 was 8.4% compared with the average European rate of 12%. These figures are in even greater contrast to reported five-year survival rates in the US of 15.7% for patients diagnosed between 1995 and 2001.4 Analysis of EUROCARE-4 also showed that one-year survival rates in England were lower than the European average, probably reflecting poorer access to care. This would suggest a particular need to promote earlier diagnosis in the UK, to try to improve survival.

Survival is dependent on the disease stage at diagnosis, with a marked variation between earlier- and later-stage disease. Five-year survival for localised disease is around 49% compared with 2% for disease with distant metastases at presentation.4 Unfortunately, the majority of lung cancers have already been disseminated at the time of presentation.4,5

Much interest has focused on diagnosing lung cancer earlier in order to try to improve radical treatment rates and reduce mortality. Initially, this interest focused on screening. The first randomised controlled trial took place in London in the 1960s.6 This looked at a chest X-ray every six months for three years versus a chest X-ray at the beginning and end of the three-year period. Diagnosis and resection rates were higher in the group receiving more frequent chest X-rays, but lung cancer mortality was similar in both groups. Three US studies7 in the 1970s and 1980s looked at the use of either chest X-ray alone or in combination with sputum cytology.

The Mayo Lung Project8 compared chest X-ray and sputum cytology every four months with standard care. Participants randomised to the standard care arm were advised to have a yearly chest X-ray and sputum cytology. This showed that resection rates increased by 14% (32–46%) in the group undergoing screening compared with the group receiving standard care alone, but no stage shift was evident. Fiveyear survival in the screened group reached 33% compared with 15% in the non-screened group.

  1. World Health Organisation, The global burden of disease: 2004 update. 2008. Geneva: WHO Press, www.who.int/healthinfo/global_burden_disease/2004_report_update/en/index.html (accessed 28 June 2010).
  2. Quinn M, Babb P, Brock A, et al., Cancer Trends in England and Wales 1950–1999. SMPS No 66. Office of National Statistics, The Stationery Office, London. 2001.
  3. Sant M, Allemani C, Santaquilani M, et al.; EUROCARE working group, EUROCARE-4 Survival of cancer patients diagnosed in 1995–1999. Results and Commentary, Eur J Cancer, 2009;45:931–91.
  4. SEER Cancer Statistics Review 1975-2006 Section 15: lung and bronchus. National Cancer Institute, www.seer. cancer.gov/csr/1975_2006/results_merged/sect_15_lung_bronchus.pdf (accessed 28 June 2010).
  5. Cancer Research UK, Lung cancer and smoking statistics: Key facts, http://info.cancerresearchuk.org/cancerstats/types/lung/index.htm (accessed 28 June 2010).
  6. Brett GZ, The value of lung cancer detection by 6-monthly chest radiographs, Thorax, 1968;23:414–20.
  7. Berlin NI, Buncher CR, Fontana RS, et al., The National Cancer Institute Cooperative Early Cancer Detection program. Results of the initial screen (prevalence). Early lung cancer detection: Introduction, Am Rev Respir Dis, 1984;130:545–9.
  8. Fontana RS, Sanderson DR, Woolner LB, et al., Screening for lung cancer: a critique of the Mayo Lung Project, Cancer, 1991;67(Suppl. 4):1155–64.
  9. Melamed MR, Flehinger BJ, Zaman MB, et al., Screening for early lung cancer. Results of the Memorial Sloan- Kettering study in New York, Chest, 1984;86:44–53.
  10. Kubík A, PoláK J, Lung Cancer Detection: Results of a Randomized Prospective Study in Czechoslovakia, Cancer, 1986;57:2427–37.
  11. Kubík AK, Parkin DM, Zatloukal P, Czech Study on Lung Cancer Screening: Post-Trial Follow Up of Lung Cancer Deaths Up to Year 15 Since Enrollment, Cancer, 2000; 89(Suppl. 11):2363–8.
  12. Manser R, Irving LB, Stone C, et al., Screening for lung cancer, Cochrane Database Syst Rev, 2004;(1):CD001991.
  13. Frost JK, Ball WC, Jr, Levin ML, et al., Early lung cancer detection: results of the initial (prevalence) radiologic and cytologic screening in the Johns Hopkins study, Am Rev Respir Dis, 1984;130:549–54.
  14. Muhm JR, Miller WE, Fontana RS, et al., Lung cancer detected during a screening programme using fourmonth chest radiographs, Radiology, 1983;148:609–15.
  15. Midthun DE, Jett JR, Chapter 4: Screening for lung cancer. In: Spiro SG, Huber RM, Janes SM (eds), Thoracic Malignancies, Eur Respir Mon, 2009;44:57–70.
  16. Kaneko M, Eguchi K, Ohmatsu et al. Peripheral lung cancer: screening and detection with low-dose spiral CT versus radiography, Radiology, 1996;201:798–802.
  17. Sone S, Takashima S, Li F, et al., Mass screening for lung cancer with mobile spiral computed tomography scanner, Lancet, 1998;351:1242–5.
  18. Henschke CI, McCauley DI, Yankelevitz DF, et al., Early Lung Cancer Action Project: overall design and findings from baseline screening, Lancet, 1999;354:99–105.
  19. The International Early Lung Cancer Action Programme Investigators. Survival of Patients with Stage I Lung Cancer Detected on CT Screening, N Engl J Med, 2006;355:1763–71.
  20. McWilliams A, Mayo J, MacDonald S, et al., Lung cancer screening: a different paradigm, Am J Respir Crit Care Med, 2003;168:1167–73.
  21. Diederich S, Wormanns D, Semik M, et al., Screening for early lung cancer with low dose spiral CT: prevalence in 817 asymptomatic smokers, Radiology, 2002;222:773–81.
  22. Swensen SJ, Jett JR, Hartman TE, et al., CT screening for lung cancer: five-year prospective experience, Radiology, 2005;235:259–65.
  23. Crestanello JA, Allen MS, Jett JR, et al., Thoracic surgical operations in patients enrolled in a computed tomography screening trial, J Thorac Cardiovasc Surg, 2004;128:254–9.
  24. Zackrisson S, Andersson I, Janzon L, et al., Rate of overdiagnosis of breast cancer 15 years after end of Mälmo mammographic screening trial: follow-up study, BMJ, 2006;332(7543):689–92.
  25. Draisma G, Boer R, Otto SJ, et al., Lead times and overdetection due to prostate-specific antigen screening: estimates from the European randomized study of screening for prostate cancer, J Natl Cancer Inst, 2003;95:868–78.
  26. Bach PB, Silvestri GA, Hanger M, et al., Screening for Lung Cancer: ACCP evidence-based clinical practice guidelines (2nd Edition), Chest, 2007;132:69S–77S.
  27. Aberle DR, Black WC, Golding JG, et al., Experimental design and outcomes of the National Lung Screening Trial (NLST): a multicenter randomized controlled trial of the helical CT vs chest X-ray for lung cancer screening (abstract), Am J Respir Crit Care Med, 2003;167:A736.
  28. UK lung cancer screening trial (UKLS) – Feasibility study and protocol development, www.hta.ac.uk/1752 (accessed 28 June 2010).
  29. van Iersel CA, de Koning HJ, Draisma G, et al., Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch- Belgian randomised lung cancer multi-slice CT screening trial (NELSON), Int J Cancer, 2006;120:868–74.
  30. McWilliams AM, Mayo JR, Ahn MI, et al., Lung cancer screening using multi-slice thin-section computed tomography and autofluorescence bronchoscopy, J Thorac Oncol, 2006;1:61–8.
  31. Ghosal R, Kloer P, Lewis KE, A review of novel biological tools used in screening for the early detection of lung cancer, Postgrad Med J, 2009;85:358–63.
  32. NHS Executive, Referral guidelines for suspected cancer, Department of Health, London, 2002.
  33. Corner J, Hopkinson J, Fitzsimmons D, et al., Is late diagnosis of lung cancer inevitable? Interview study of patients’ recollections of symptoms before diagnosis, Thorax, 2005;60:314–19.
  34. Buccheri G, Ferrigno D, Lung cancer: Clinical presentation and specialist referral time, Eur Respir J, 2004;24:98–904.
  35. Smith SM, Campbell NC, MacLeod U, et al., Factors contributing to the time taken to consult with symptoms of lung cancer: a cross sectional study, Thorax, 2009;64: 523–31.
  36. Koyi H, Hillerdal G, Brandén E, Patient’s and doctors’ delays in the diagnosis of chest tumours, Lung Cancer, 2002;35:53–7.
  37. Bowen EF, Raynor CFJ, Patient and GP led delays in the recognition of symptoms suggestive of lung cancer, Lung Cancer, 2002;37:227–8.
  38. Salomaa E-R, Sällinen S, Hiekkanen H, et al., Delays in the diagnosis and treatment of lung cancer, Chest, 2005;128: 2282–8.
  39. Lövgren M, Leveälahti H, Tishelman C, et al., Time spans from first symptom to treatment in patients with lung cancer – The influence of symptoms and demographic characteristics, Acta Oncologica, 2008;47:397–405.
  40. Corner J, Hopkinson J, Roffe J, Experience of health changes and reasons for delay in seeking care: A UK study of the months prior to the diagnosis of lung cancer, Soc Sci Med, 2006;62:1381–91.
  41. Tod A, Craven J, Allmark P, Diagnostic delay in lung cancer: a qualitative study, J Adv Nurs, 2008;61(3):336–43.
  42. National Institute for Clinical Excellence. Lung Cancer: NICE guidelines 2005, www.nice.org.uk/CG024 guidelines (accessed 28 June 2010).
  43. Jones RVH, Dudgeon TA, Time between presentation and treatment of six common cancers: a study in Devon, Br J Gen Pract, 1992;42:419–22.
  44. Annakkaya AN, Arbak P, Balbay O, et al., Effect of symptom-to-treatment interval on prognosis in lung cancer, Tumori, 2007;93:61–7.
  45. Bjerager M, Palshof T, Dahl R, et al., Delay in the diagnosis of lung cancer in general practice, Br J Gen Pract, 2006;56:863–8.
  46. Barrett J, Hamilton W, Pathways to the diagnosis of lung cancer in the UK: a cohort study, BMC Family Practice, 2008;9:31.
  47. Department of Health: Cancer Reform Strategy, Crown, 2007, www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_081007.pdf (accessed 28 June 2010).
  48. Abdel-Rehman M, Stockton D, Rachet B, et al., What if cancer survival in Britain was the same as in Europe: how many deaths are avoidable?, Br J Cancer, 2009;101:S115–24.
  49. Richards MA, The National Awareness and Early Detection Initiative in England: assembling the evidence, Br J Cancer, 2009;101:S1–4.
  50. Evans WD, McCormack L, Applying Social Marketing in Health Care: Communicating Evidence to Change Consumer Behaviour, Med Decis Making, 2008;28:781.
  51. Hastings G, McDermott L, Putting social marketing into practice, BMJ, 2006;332:1210–12.
  52. Tod AM, Suckling R, Early Lung Cancer Identification in Doncaster (ELCID), Lung Cancer, 2009;63(1):S19.
  53. Rogers TK, Athey V, Tod A, et al., Early detection of lung cancer: A social marketing evaluation, Thorax, 2009;64 (Suppl. IV):A21.
  54. Social marketing boosts early detection of lung cancer in Doncaster, www.info.cancerresearchuk.org/spotcancerearly/naedi/local-activity/socialmarketing/index.htm (accessed 28 June 2010).
Keywords: Lung cancer, early diagnosis, screening, social marketing
Customize This